基本信息 产品详情 公司简介 推荐产品
网站主页 匹维奇单抗
  • (Pivekimab)Biosimilar Reference Antibody-GS40551
  • (Pivekimab)Biosimilar Reference Antibody-GS40551
  • (Pivekimab)Biosimilar Reference Antibody-GS40551

1/3

(Pivekimab)Biosimilar Reference Antibody-GS40551

Pivekimab
300 100μg 起订
湖北 更新日期:2026-03-12

武汉迈思生物科技有限公司

VIP1年
联系人:市场
电话:027-65523427拨打
手机:18007167883 拨打
邮箱:Service@mabnus.com

产品详情:

英文名称:
Pivekimab
CAS号:
2234335-84-1
品牌:
Mabnus
产地:
武汉
保存条件:
store at -20°C or -80°C. Avoid repeated freeze.
纯度规格:
>95% by SDS-PAGE
重组:
应用:
ELISA;FC;Functional Assays;IF
种属反应性:
Human
宿主:
Chimeric and/or humanised
偶联物:
靶点:
IL3RA/CD123
免疫原:
IL3RA/CD123
亚型:
IgG1 - kappa
验证方法:
(Pivekimab)Biosimilar Reference Antibody(GS40551) on SDS-PAGE under non-reducing (NR) and reducing (R) condition.

货号:GS40551

Pivekimab is a novel human IgG1 monoclonal antibody designed for targeted immunotherapy, which uniquely and simultaneously binds to both interleukin-3 (IL-3) and its receptor subunit CD123. This dual-targeting mechanism is intended to disrupt the IL-3 signaling pathway by sequestering the cytokine and blocking its interaction with the receptor on the cell surface. Developed primarily for the treatment of certain hematologic malignancies, pivekimab aims to inhibit the survival and proliferation of cancerous cells, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML) cells, that often overexpress CD123 and depend on IL-3 for growth and survival.


Pivekimab;

公司简介

武汉迈思生物科技有限公司立足于解决行业内功能活性蛋白表达及高亲和力、高灵敏度抗体开发难的痛点,依托自建的两大核心技术平台:哺乳动物细胞蛋白表达平台和单个B细胞抗体开发平台,竭诚为广大科研机构、高等院校、IVD企业、医药企业等提供一站式蛋白表达及抗体开发相关产品和技术服务。

成立日期 (5年)
注册资本 壹佰伍拾万圆人民币
员工人数 10-50人
年营业额 ¥ 1000万-5000万
经营模式 工厂,试剂,定制,服务
主营行业 抗体,蛋白组学

Pivekimab相关厂家报价

内容声明
拨打电话 立即询价